NCT02509728

Brief Summary

To explore the effects of enteral choline and DHA supplementation on plasma choline and DHA-PC concentrations and metabolism, this randomized controlled study will assign 40 preterm infants to 1 of 4 groups: standard care, choline supplementation, DHA supplementation, and choline and DHA supplementation. After 7 days of supplementation, a single dose of stable isotope labelled choline will be administered and the kinetics of newly synthesized DHA-PC determined to assess plasma levels, uptake and distribution of choline and DHA. This study is designed to inform larger studies evaluating this approach of enteral co-application of choline and DHA on clinical important outcomes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

July 22, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 28, 2015

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2017

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2017

Completed
Last Updated

May 15, 2018

Status Verified

May 1, 2018

Enrollment Period

2.3 years

First QC Date

July 22, 2015

Last Update Submit

May 9, 2018

Conditions

Keywords

cholinedocosahexaenoic acid

Outcome Measures

Primary Outcomes (1)

  • plasma concentrations of choline

    following 7 days of supplementation

Secondary Outcomes (7)

  • de-novo DHA-phosphatidylcholine synthesis

    following 7 days of supplementation at 12hours after D9-choline administration

  • DHA-phosphatidylcholine turnover

    following 7.5 days of supplementation, from 12hours to 60 hours after D9-choline administration

  • fractions and concentrations of molecular species of phosphatidylcholine

    baseline and following 7.5 and 10 days of supplementation

  • plasma concentrations of choline

    baseline and following 7.5 and 10 days of supplementation

  • Plasma concentrations of betaine (a metabolite of choline)

    baseline and following 7.5 and 10 days of supplementation

  • +2 more secondary outcomes

Study Arms (4)

standard nutrition

ACTIVE COMPARATOR

standard nutrition

Dietary Supplement: standard nutrition

choline supplementation

EXPERIMENTAL

in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days

Dietary Supplement: choline supplementationDietary Supplement: standard nutrition

DHA supplementation

EXPERIMENTAL

in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days

Dietary Supplement: DHA supplementationDietary Supplement: standard nutrition

choline and DHA supplementation

EXPERIMENTAL

in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride and 60mg/kg of DHA for 10 days

Dietary Supplement: choline supplementationDietary Supplement: DHA supplementationDietary Supplement: standard nutrition

Interventions

choline supplementationDIETARY_SUPPLEMENT

in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days

choline and DHA supplementationcholine supplementation
DHA supplementationDIETARY_SUPPLEMENT

in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days

DHA supplementationcholine and DHA supplementation
standard nutritionDIETARY_SUPPLEMENT

standard nutrition

DHA supplementationcholine and DHA supplementationcholine supplementationstandard nutrition

Eligibility Criteria

Age1 Week - 2 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • preterm infants with a gestational age at birth between 24 and 32 weeks
  • on almost complete enteral feeding (\>75% of total fluid intake)

You may not qualify if:

  • insufficient enteral intake,
  • gastrointestinal disease,
  • missing parental consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of Tuebingen

Tübingen, 72076, Germany

Location

Related Publications (4)

  • Bernhard W, Raith M, Kunze R, Koch V, Heni M, Maas C, Abele H, Poets CF, Franz AR. Choline concentrations are lower in postnatal plasma of preterm infants than in cord plasma. Eur J Nutr. 2015 Aug;54(5):733-41. doi: 10.1007/s00394-014-0751-7. Epub 2014 Aug 23.

    PMID: 25148882BACKGROUND
  • Bernhard W, Raith M, Koch V, Kunze R, Maas C, Abele H, Poets CF, Franz AR. Plasma phospholipids indicate impaired fatty acid homeostasis in preterm infants. Eur J Nutr. 2014 Oct;53(7):1533-47. doi: 10.1007/s00394-014-0658-3. Epub 2014 Jan 24.

    PMID: 24464176BACKGROUND
  • Bernhard W, Full A, Arand J, Maas C, Poets CF, Franz AR. Choline supply of preterm infants: assessment of dietary intake and pathophysiological considerations. Eur J Nutr. 2013 Apr;52(3):1269-78. doi: 10.1007/s00394-012-0438-x. Epub 2012 Sep 9.

    PMID: 22961562BACKGROUND
  • Bernhard W, Bockmann K, Maas C, Mathes M, Hovelmann J, Shunova A, Hund V, Schleicher E, Poets CF, Franz AR. Combined choline and DHA supplementation: a randomized controlled trial. Eur J Nutr. 2020 Mar;59(2):729-739. doi: 10.1007/s00394-019-01940-7. Epub 2019 Mar 11.

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Axel Franz, MD

    University Hospital Tuebingen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 22, 2015

First Posted

July 28, 2015

Study Start

July 1, 2015

Primary Completion

October 31, 2017

Study Completion

December 31, 2017

Last Updated

May 15, 2018

Record last verified: 2018-05

Locations